Francesca Fazio

10PUBLICATIONS
56CO-AUTHORS
Haematological tumoursPredictive and prognostic markersMedical mycologyRegenerative medicine (incl. stem cells)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Aug 18, 2026
Salvage treatment patterns in multiple myeloma patients progressing after lenalidomide maintenance: A real-life study from European Myeloma Network (EMN) Italy.

|Jun 18, 2026
Vaccination and Antiviral Combination Improves Resolution Time of COVID-19 Infection in Treated Multiple Myeloma: A Retrospective Study.

|Nov 28, 2025
Targeting RNA polymerase I to boost natural killer cell anticancer activity in multiple myeloma.

Elena Sproviero, Eleonora Gnocchini, Tommaso Cipollone

|Nov 13, 2025
The Strange Case of Functional High-Risk Multiple Myeloma Patients: Is It Possible to Identify Them in Clinical Practice?

Sonia Morè, Massimo Offidani, Laura Corvatta

|Jun 27, 2025
Correction: Sgherza et al. Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study. Pharmaceuticals 2025, 18, 595.

Nicola Sgherza, Olga Battisti, Paola Curci

|Apr 26, 2025
Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study.

Nicola Sgherza, Olga Battisti, Paola Curci

Pageof 2

Frequent Collaborators

4 joint publications

Maria Teresa Petrucci

4 joint publications

Giuseppe Mele

4 joint publications

Carmine Liberatore

4 joint publications

Massimo Offidani